Skip to Content

Generic Contrave Availability

Contrave is a brand name of bupropion/naltrexone, approved by the FDA in the following formulation(s):

CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride - tablet, extended release;oral)

  • Manufacturer: OREXIGEN
    Approval date: September 10, 2014
    Strength(s): 90MG;8MG [RLD]

Has a generic version of Contrave been approved?

No. There is currently no therapeutically equivalent version of Contrave available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Contrave. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions for affecting weight loss
    Patent 7,375,111
    Issued: May 20, 2008
    Inventor(s): Weber; Eckard & Cowley; Michael Alexander
    Assignee(s): Orexigen Therapeutics, Inc.
    Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
    Patent expiration dates:
    • March 26, 2025
      ✓ 
      Drug product
  • Compositions for affecting weight loss
    Patent 7,462,626
    Issued: December 9, 2008
    Inventor(s): Weber; Eckard & Cowley; Michael Alexander
    Assignee(s): Orexigen Therapeutics, Inc.
    Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
    Patent expiration dates:
    • July 20, 2024
      ✓ 
      Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
  • Layered pharmaceutical formulations
    Patent 8,088,786
    Issued: January 3, 2012
    Inventor(s): McKinney; Anthony & Tollefson; Gary & Weber; Eckard & Soltero; Rick
    Assignee(s): Orexigen Therapeutics, Inc.
    In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
    Patent expiration dates:
    • February 3, 2029
      ✓ 
      Drug product
  • Layered pharmaceutical formulations
    Patent 8,318,788
    Issued: November 27, 2012
    Inventor(s): McKinney; Anthony & Tollefson; Gary & Weber; Eckard & Soltero; Rick
    Assignee(s): Orexigen Therapeutics, Inc.
    In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
    Patent expiration dates:
    • November 8, 2027
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
  • Methods for administering weight loss medications
    Patent 8,722,085
    Issued: May 13, 2014
    Assignee(s): Orexigen Therapeutics, Inc.
    Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Patent expiration dates:
    • November 8, 2027
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
  • Compositions and methods for increasing insulin sensitivity
    Patent 8,815,889
    Issued: August 26, 2014
    Assignee(s): Orexigen Therapeutics, Inc.
    Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Patent expiration dates:
    • July 20, 2024
      ✓ 
      Patent use: FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
  • Sustained release formulation of naltrexone
    Patent 8,916,195
    Issued: December 23, 2014
    Assignee(s): Orexigen Therapeutics, Inc.
    A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Patent expiration dates:
    • February 2, 2030
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
  • Sustained release formulation of naltrexone
    Patent 9,107,837
    Issued: August 18, 2015
    Assignee(s): Orexigen Therapeutics, Inc.
    A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Patent expiration dates:
    • June 4, 2027
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
  • Methods for administering weight loss medications
    Patent 9,125,868
    Issued: September 8, 2015
    Assignee(s): OREXIGEN THERAPEUTICS, INC.
    Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Patent expiration dates:
    • November 8, 2027
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
  • Methods of providing weight loss therapy in patients with major depression
    Patent 9,248,123
    Issued: February 2, 2016
    Assignee(s): Orexigen Therapeutics, Inc.
    Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Patent expiration dates:
    • January 13, 2032
      ✓ 
      Patent use: USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATINETS WITH MAJOR DEPRESSIVE DISORDER

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 10, 2017 - NEW COMBINATION

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide